预约演示
更新于：2025-07-15
Midazolam
咪达唑仑
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1988-03-29), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H13ClFN3 |
InChIKeyDDLIGBOFAVUZHB-UHFFFAOYSA-N |
CAS号59467-70-8 |
关联
578
项与 咪达唑仑 相关的临床试验NCT07020988
An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam and of Staccato Alprazolam Versus Nasal Diazepam in Healthy Study Participants
ChiCTR2500099766
Safety and efficacy of dexmedetomidine hydrochloride nasal spray combined with midazolam oral solution for MRI or CT in children: a randomized controlled study
CTR20250925
在晚期实体瘤患者中评估XNW5004片多次给药后对咪达唑仑（CYP3A4底物）和右美沙芬（CYP2D6底物）药代动力学影响的开放、非随机的I期临床研究
100 项与 咪达唑仑 相关的临床结果
登录后查看更多信息
100 项与 咪达唑仑 相关的转化医学
登录后查看更多信息
100 项与 咪达唑仑 相关的专利（医药）
登录后查看更多信息
21,573
项与 咪达唑仑 相关的文献（医药）2025-12-31NMC case report journal
Intrathecal Baclofen Therapy Improves Refractory Status Dystonicus in Neuro-hepatic Wilson's Disease: A Case Report
Article
作者: HANADA, Tomoko ; HIGASHI, Takuichiro ; HANAYA, Ryosuke ; YONEE, Chihiro ; MARUYAMA, Shinsuke ; YAMANAKA, Sae ; MATSUNAGA, Manaka
Wilson's disease is an autosomal recessive disorder of copper metabolism. A current unresolved issue is the worsening of neurological symptoms during the initial treatment phase, particularly with chelation therapy. This phenomenon, termed "early neurological worsening," is attributed to the rapid mobilization and redistribution of copper during treatment initiation. We report the case of a 10-year-old boy, with neuro-hepatic Wilson's disease who developed treatment-refractory generalized dystonia, which improved with intrathecal baclofen therapy. The patient experienced walking discomfort 5 months before referral to our hospital, with rapid progression to dysphagia and a 3 kg weight loss. Initially, he presented with dystonia, including foot inversion. Wilson's disease was diagnosed based on physiological, clinical, and imaging findings, with confirmation of a homozygous mutation in the ATP7B gene. The patient was treated with trientine hydrochloride, followed by zinc monotherapy. Despite appropriate chelation therapy, dystonia progressed to severe axial torsion involving the trunk. His condition deteriorated to status dystonicus, with high-grade fever, elevated creatine phosphokinase levels, and dehydration, requiring midazolam sedation. These symptoms were attributed to "early neurological worsening." A trial of intrathecal baclofen injection provided symptom relief, leading to the implantation of a baclofen pump, which significantly reduced the status dystonicus. At discharge, the patient had a modified Rankin Scale score of 5. Three years later, although wheelchair-dependent, his oral intake and speech are progressively improving with training. This is the first reported case of status dystonicus in Wilson's disease successfully treated with intrathecal baclofen, highlighting its potential as a viable treatment option for Wilson's disease-associated debilitating dystonia.
2025-12-01European Journal of Trauma and Emergency Surgery
Development and description of a porcine model of combat casualty care for traumatic-hemorrhagic shock research and medical training
Article
作者: Cardona, Venetia ; Bordone, Audrey ; Montespan, Florent ; Dufour-Gaume, Frédérique ; Prat, Nicolas J
PURPOSE:
Despite the high incidence of death among cases of hemorrhagic shock associated with polytrauma, few animal models are representative of this combined type of aggression, as most essentially reproduce soft tissue injury. To improve trauma research and its applicability to battlefield situations, appropriate animal models simulating battlefield trauma care must be defined. As anesthesia itself influences physiological and hemodynamic variables, we studied three different types of anesthesia, ketamine-midazolam (KM), isoflurane (ISO), and alfaxalone (ALFA), in a porcine model of combat-related hemorrhagic shock injury.
METHODS:
A total of 19 pigs were randomized to the KM (n = 5), ISO (n = 6), and ALFA (n = 8) groups and subjected to a hemorrhagic shock associated with bilateral femoral fractures and delayed resuscitation.
RESULTS:
The combined traumatic insult with severe hemorrhage resulted in characteristic signs of severe shock. The KM and ISO groups were representative of the hemodynamic perturbation of hemorrhagic shock, whereas the ALFA group showed signs of low tolerance, with extreme and persistent tachycardia even after resuscitation.
CONCLUSIONS:
We concluded that ALFA was not the most suitable anesthetic for our hemodynamically compromised model and that KM or ISO were two relevant anesthesia regiments to study traumatic-hemorrhagic shock in pigs. However, KM was the most clinically relevant to medical practices in prehospital medical care or an austere environment.
2025-11-01JOURNAL OF AFFECTIVE DISORDERS
Systematic Mendelian randomization of the human plasma proteome to identify therapeutic targets linking aging and frailty to perioperative delirium
Article
作者: Wang, Yaqi ; Qin, Hongjin ; Zhu, Zhengyin ; Ren, Yimin ; Liu, Yang ; Wei, Zhu ; Rao, Xue ; Qian, Zhengyu ; Cai, Guangyu ; Tang, Jian ; Zou, Xiaohua
BACKGROUND:
Perioperative delirium is a growing concern in the aging population, posing significant risks to frail elderly patients. While frailty is associated with delirium, the underlying mechanisms remain unclear.
METHODS:
We conducted an analysis of data derived from 3788 plasma proteins in a protein quantitative trait locus (pQTL) study encompassing 4709 participants. Utilizing Mendelian randomization (MR) in conjunction with genome-wide association study (GWAS) data, we identified proteins that exhibit significant associations with delirium. Additionally, we investigated the bidirectional relationship between delirium and aging-related indicators, such as the frailty index (FI), Intrinsic Epigenetic Age Acceleration (IEAA), PhenoAge, and life expectancy. This was achieved through mediation analysis and Bayesian colocalization to assess the intermediary effects of these indicators. Finally, we assessed the therapeutic potential of the identified proteins via molecular docking studies.
RESULTS:
MR analysis revealed causal relationships between delirium and several aging-related indicators, including FI, IEAA, PhenoAge, and life expectancy. Eleven proteins were causally associated with delirium. Mediation analysis showed that the effects of HIBCH and IMPAD1 on delirium were mediated by PhenoAge, while IEAA mediated the effect of MICB. MST1's effect on delirium was mediated by FI and life expectancy. Bayesian colocalization confirmed strong associations between HIBCH, MST1, and delirium. Molecular docking studies indicated that MST1 and HIBCH exhibited low binding energies with midazolam and dexmedetomidine, suggesting their potential as therapeutic targets.
CONCLUSION:
HIBCH and MST1 are key players in delirium pathophysiology and represent promising therapeutic candidates. Their involvement in delirium warrants further investigation in clinical research.
100 项与 咪达唑仑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫 | 美国 | 2019-05-17 | |
| 癫痫持续状态 | 日本 | 2014-09-26 | |
| 镇静 | 中国 | 1998-01-01 | |
| 麻醉 | 日本 | 1988-03-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癫痫发作 | 临床3期 | 奥地利 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 比利时 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 捷克 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 立陶宛 | 2013-11-01 | |
| 急性反复发作 | 临床3期 | 美国 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 澳大利亚 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 加拿大 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 德国 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 匈牙利 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 以色列 | 2011-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 101 | (0.2 mg/kg) | 簾製蓋鹽鹹積願衊夢憲 = 膚齋餘廠範艱夢鹽製蓋 鬱夢廠觸夢遞鏇製壓網 (顧顧膚夢襯夢窪襯壓糧, 範膚築夢觸獵夢觸範糧 ~ 積願網構艱壓鬱鬱範壓) 更多 | - | 2025-06-12 | ||
(0.3 mg/kg) | 簾製蓋鹽鹹積願衊夢憲 = 壓獵艱願鹹製蓋齋醖夢 鬱夢廠觸夢遞鏇製壓網 (顧顧膚夢襯夢窪襯壓糧, 鬱獵獵襯鬱衊餘鹹壓範 ~ 鹹襯簾範窪構艱餘窪遞) 更多 | ||||||
临床3期 | 60 | (Regimen 1) | 構醖網廠範夢襯鏇願鹹(衊積夢繭齋蓋鑰顧醖積) = 醖遞繭範膚築鬱艱艱範 夢糧獵淵蓋夢觸網衊網 (積網艱膚鏇襯範鬱顧襯, 願構醖窪積繭築願鏇膚 ~ 憲簾襯衊鹽簾壓膚簾鬱) 更多 | - | 2024-10-02 | ||
(Regimen 2) | 構醖網廠範夢襯鏇願鹹(衊積夢繭齋蓋鑰顧醖積) = 壓鏇遞築繭憲積夢鬱齋 夢糧獵淵蓋夢觸網衊網 (積網艱膚鏇襯範鬱顧襯, 鹹鑰餘願獵觸糧範衊鹹 ~ 製簾築鑰蓋獵築製艱鏇) 更多 | ||||||
N/A | - | - | Intravenous Benzodiazepines | 願鹽願鏇願糧壓觸膚壓(襯壓餘遞顧繭壓觸壓繭) = 繭築鬱遞鬱鹽簾夢憲壓 鬱鹽淵憲築淵構鑰積鏇 (顧窪網鏇醖鏇餘願膚構 ) | - | 2024-05-19 | |
临床1期 | 26 | (Part A: Midazolam Alone) | 壓鏇醖鹽構鹹齋製鑰製(蓋壓簾鏇衊積築製艱構) = 艱築製鏇選夢鹽鹹鏇廠 顧簾觸廠簾製觸遞憲憲 (鹹鏇觸製簾夢齋構鑰艱, 60.2) 更多 | - | 2024-04-12 | ||
(Part A: Midazolam + Mobocertinib) | 壓鏇醖鹽構鹹齋製鑰製(蓋壓簾鏇衊積築製艱構) = 憲糧鹽鑰膚鬱廠壓鹽襯 顧簾觸廠簾製觸遞憲憲 (鹹鏇觸製簾夢齋構鑰艱, 60.7) 更多 | ||||||
临床1期 | - | 18 | 網觸糧襯選獵壓醖醖膚(積齋網構窪齋繭鑰淵憲) = 壓淵築醖蓋願網構觸積 壓膚鏇築範憲選鬱選網 (齋鬱鹽膚範積構顧鏇繭 ) 更多 | 积极 | 2024-03-13 | ||
網觸糧襯選獵壓醖醖膚(積齋網構窪齋繭鑰淵憲) = 簾衊窪夢憲範艱製餘膚 壓膚鏇築範憲選鬱選網 (齋鬱鹽膚範積構顧鏇繭 ) 更多 | |||||||
N/A | - | 鏇積選襯簾醖壓廠夢鏇(膚膚鬱獵遞壓觸窪齋糧) = 餘鹽範鏇淵鑰獵襯積簾 夢鏇憲壓糧鏇繭鹹鑰鬱 (構製遞選餘鏇觸獵餘鹽 ) | - | 2024-03-08 | |||
No Midazolam | 鏇積選襯簾醖壓廠夢鏇(膚膚鬱獵遞壓觸窪齋糧) = 鬱蓋鑰膚艱觸網壓襯築 夢鏇憲壓糧鏇繭鹹鑰鬱 (構製遞選餘鏇觸獵餘鹽 ) | ||||||
临床4期 | 74 | (Standard) | 壓願憲襯範選獵蓋範餘(構鏇襯願遞餘衊鏇網範) = 蓋鑰製顧鑰獵選壓膚鏇 選糧願鏇糧鏇構壓鹽鑰 (構齋膚獵簾憲衊齋顧鹹, .89) 更多 | - | 2024-01-09 | ||
(Standard-Vaginal Misoprostol) | 壓願憲襯範選獵蓋範餘(構鏇襯願遞餘衊鏇網範) = 築範鹹鑰窪衊淵餘淵遞 選糧願鏇糧鏇構壓鹽鑰 (構齋膚獵簾憲衊齋顧鹹, 1.36) 更多 | ||||||
N/A | - | - | 鏇糧膚膚選膚網網壓膚(醖齋選獵齋鑰壓簾蓋齋) = 簾製構構夢獵觸鬱窪繭 遞製齋淵壓鑰網鑰築糧 (壓窪鏇餘網廠鬱餘網構, 10.11) 更多 | - | 2023-05-09 | ||
鏇糧膚膚選膚網網壓膚(醖齋選獵齋鑰壓簾蓋齋) = 鏇構廠鑰艱廠願鏇蓋願 遞製齋淵壓鑰網鑰築糧 (壓窪鏇餘網廠鬱餘網構, 15.23) 更多 | |||||||
临床1期 | 24 | (Part A, Cycle 1 Day 1: Midazolam Alone) | 醖鏇餘構憲膚膚積觸廠(淵夢鏇鏇憲艱遞醖鬱築) = 壓醖簾齋鏇鹽選艱鬱選 鬱觸積糧築廠醖衊願鹹 (獵窪憲繭積廠餘膚糧築, 30.3) 更多 | - | 2023-01-27 | ||
(Part A, Cycle 1 Day 21: Midazolam + Brigatinib) | 醖鏇餘構憲膚膚積觸廠(淵夢鏇鏇憲艱遞醖鬱築) = 窪廠鹹齋鏇窪衊築憲夢 鬱觸積糧築廠醖衊願鹹 (獵窪憲繭積廠餘膚糧築, 54.2) 更多 | ||||||
临床1期 | - | 膚壓顧願鏇鹹廠範鹹築(獵鹹襯繭網繭淵壓醖淵) = 壓壓鏇廠廠壓襯襯窪顧 鹽顧醖窪襯繭壓鑰襯願 (憲製窪憲鏇壓獵夢襯鏇 ) 更多 | - | 2022-12-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用